157 related articles for article (PubMed ID: 37667329)
1. ERCC6L facilitates the onset of mammary neoplasia and promotes the high malignance of breast cancer by accelerating the cell cycle.
Yang H; Zhen X; Yang Y; Zhang Y; Zhang S; Hao Y; Du G; Wang H; Zhang B; Li W; Wang J
J Exp Clin Cancer Res; 2023 Sep; 42(1):227. PubMed ID: 37667329
[TBL] [Abstract][Full Text] [Related]
2. shRNA knockdown of DNA helicase ERCC6L expression inhibits human breast cancer growth.
Liu J; Sun J; Zhang Q; Zeng Z
Mol Med Rep; 2018 Sep; 18(3):3490-3496. PubMed ID: 30066865
[TBL] [Abstract][Full Text] [Related]
3. ERCC6L facilitates the progression of laryngeal squamous cell carcinoma by the binding of FOXM1 and KIF4A.
Cui M; Chang Y; Wang J; Wu J; Li G; Tan J
Cell Death Discov; 2023 Feb; 9(1):41. PubMed ID: 36726012
[TBL] [Abstract][Full Text] [Related]
4. ERCC6L, a DNA helicase, is involved in cell proliferation and associated with survival and progress in breast and kidney cancers.
Pu SY; Yu Q; Wu H; Jiang JJ; Chen XQ; He YH; Kong QP
Oncotarget; 2017 Jun; 8(26):42116-42124. PubMed ID: 28178669
[TBL] [Abstract][Full Text] [Related]
5. Roles of BCCIP deficiency in mammary tumorigenesis.
Droz-Rosario R; Lu H; Liu J; Liu NA; Ganesan S; Xia B; Haffty BG; Shen Z
Breast Cancer Res; 2017 Oct; 19(1):115. PubMed ID: 29047390
[TBL] [Abstract][Full Text] [Related]
6. ERCC6L that is up-regulated in high grade of renal cell carcinoma enhances cell viability in vitro and promotes tumor growth in vivo potentially through modulating MAPK signalling pathway.
Zhang G; Yu Z; Fu S; Lv C; Dong Q; Fu C; Kong C; Zeng Y
Cancer Gene Ther; 2019 Sep; 26(9-10):323-333. PubMed ID: 30459398
[TBL] [Abstract][Full Text] [Related]
7. ERCC6L promotes the progression of hepatocellular carcinoma through activating PI3K/AKT and NF-κB signaling pathway.
Chen H; Wang H; Yu X; Zhou S; Zhang Y; Wang Z; Huang S; Wang Z
BMC Cancer; 2020 Sep; 20(1):853. PubMed ID: 32891122
[TBL] [Abstract][Full Text] [Related]
8. Overexpression of ERCC6L correlates with poor prognosis and confers malignant phenotypes of lung adenocarcinoma.
Huang X; Jiang L; Lu S; Yuan M; Lin H; Li B; Wen Z; Zhong Y
Oncol Rep; 2022 Jul; 48(1):. PubMed ID: 35656882
[TBL] [Abstract][Full Text] [Related]
9. CDK16 promotes the progression and metastasis of triple-negative breast cancer by phosphorylating PRC1.
Li X; Li J; Xu L; Wei W; Cheng A; Zhang L; Zhang M; Wu G; Cai C
J Exp Clin Cancer Res; 2022 Apr; 41(1):149. PubMed ID: 35449080
[TBL] [Abstract][Full Text] [Related]
10. Absence of integrin α3β1 promotes the progression of HER2-driven breast cancer in vivo.
Ramovs V; Secades P; Song JY; Thijssen B; Kreft M; Sonnenberg A
Breast Cancer Res; 2019 May; 21(1):63. PubMed ID: 31101121
[TBL] [Abstract][Full Text] [Related]
11. Deubiquitylase YOD1 regulates CDK1 stability and drives triple-negative breast cancer tumorigenesis.
Han Z; Jia Q; Zhang J; Chen M; Wang L; Tong K; He W; Zhang Y; Zhu W; Qin J; Wang T; Liu T; Ma Y; Chen Y; Zha S; Zhang C
J Exp Clin Cancer Res; 2023 Sep; 42(1):228. PubMed ID: 37667382
[TBL] [Abstract][Full Text] [Related]
12. ERCC6L promotes cell growth and metastasis in gastric cancer through activating NF-κB signaling.
Chen D; Liu Q; Cao G
Aging (Albany NY); 2021 Aug; 13(16):20218-20228. PubMed ID: 34425559
[TBL] [Abstract][Full Text] [Related]
13. CIP2A Interacts with TopBP1 and Drives Basal-Like Breast Cancer Tumorigenesis.
Laine A; Nagelli SG; Farrington C; Butt U; Cvrljevic AN; Vainonen JP; Feringa FM; Grönroos TJ; Gautam P; Khan S; Sihto H; Qiao X; Pavic K; Connolly DC; Kronqvist P; Elo LL; Maurer J; Wennerberg K; Medema RH; Joensuu H; Peuhu E; de Visser K; Narla G; Westermarck J
Cancer Res; 2021 Aug; 81(16):4319-4331. PubMed ID: 34145035
[TBL] [Abstract][Full Text] [Related]
14. Targeted Pten deletion plus p53-R270H mutation in mouse mammary epithelium induces aggressive claudin-low and basal-like breast cancer.
Wang S; Liu JC; Kim D; Datti A; Zacksenhaus E
Breast Cancer Res; 2016 Jan; 18(1):9. PubMed ID: 26781438
[TBL] [Abstract][Full Text] [Related]
15. Contributions of the RhoA guanine nucleotide exchange factor Net1 to polyoma middle T antigen-mediated mammary gland tumorigenesis and metastasis.
Zuo Y; Ulu A; Chang JT; Frost JA
Breast Cancer Res; 2018 May; 20(1):41. PubMed ID: 29769144
[TBL] [Abstract][Full Text] [Related]
16. Estrogen promotes estrogen receptor negative BRCA1-deficient tumor initiation and progression.
Wang C; Bai F; Zhang LH; Scott A; Li E; Pei XH
Breast Cancer Res; 2018 Jul; 20(1):74. PubMed ID: 29996906
[TBL] [Abstract][Full Text] [Related]
17. Identification of fibroblast growth factor-8b target genes associated with early and late cell cycle events in breast cancer cells.
Nilsson EM; Brokken LJ; Narvi E; Kallio MJ; Härkönen PL
Mol Cell Endocrinol; 2012 Jul; 358(1):104-15. PubMed ID: 22465097
[TBL] [Abstract][Full Text] [Related]
18. Metabotropic glutamate receptor-1 contributes to progression in triple negative breast cancer.
Banda M; Speyer CL; Semma SN; Osuala KO; Kounalakis N; Torres Torres KE; Barnard NJ; Kim HJ; Sloane BF; Miller FR; Goydos JS; Gorski DH
PLoS One; 2014; 9(1):e81126. PubMed ID: 24404125
[TBL] [Abstract][Full Text] [Related]
19. The atypical cyclin-like protein Spy1 overrides p53-mediated tumour suppression and promotes susceptibility to breast tumourigenesis.
Fifield BA; Qemo I; Kirou E; Cardiff RD; Porter LA
Breast Cancer Res; 2019 Dec; 21(1):140. PubMed ID: 31829284
[TBL] [Abstract][Full Text] [Related]
20. KIF4A facilitates cell proliferation via induction of p21-mediated cell cycle progression and promotes metastasis in colorectal cancer.
Hou PF; Jiang T; Chen F; Shi PC; Li HQ; Bai J; Song J
Cell Death Dis; 2018 May; 9(5):477. PubMed ID: 29706624
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
